Essential Tremor – Drugs In Development, 2024
Powered by
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Essential Tremor – Drugs In Development, 2024 report and make more profitable business decisions.
Essential tremor, formerly known as benign essential tremor or familial tremor, stands as one of the most prevalent movement disorders. Defined by a tremor in hands and arms during action, it may also impact the head, voice, or lower limbs without additional neurological signs. Onset can occur at any age, with adolescence and middle age (between 40 and 50) being common. The tremor’s progression varies, from remaining mild to slowly worsening. While the exact cause is unknown, studies indicate that mild cerebellar degeneration accompanies essential tremor, affecting the brain’s movement coordination center. In 50-70% of cases, it is an inherited condition, often manifesting early in life as familial tremor.
The Essential Tremor drugs in development market research report provide comprehensive information on the therapeutics under development for Essential Tremor, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Essential Tremor and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
Quick View – Essential Tremor | Key Targets |
|
|
Key Mechanisms of Action |
|
||
Key Routes of Administration |
|
||
Key Molecule Types |
|
||
Major Companies |
|
Scope
- Therapeutics in Development: Covering 18 molecules, with 17 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Essential Tremor therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Essential Tremor pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Essential Tremor treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
AbbVie IncAfaSci Inc
ES Therapeutics LLC
GABA Therapeutics Inc
Gerbera Therapeutics Ltd
Jazz Pharmaceuticals Plc
Merz Pharma GmbH & Co KgaA
Neurocrine Biosciences Inc
Nissan Chemical Corp
Novartis AG
OB Pharmaceuticals
Praxis Precision Medicines Inc
Puretech Health Plc
Sage Therapeutics Inc
University of California San Diego